Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 ...

However, both companies are likely to survive their current headwinds and thrive over the long term. If you are willing to ...

On Tuesday, Dec. 9, Pfizer struck a $2.1 billion licensing deal with China’s YaoPharma to develop a GLP-1 weight loss pill ...

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.

Pfizer ( ($PFE) ) has provided an announcement. On December 16, 2025, Pfizer announced its financial guidance for the full year 2026, while ...

The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

BME’s portfolio is a who’s-who of medical-device makers. What’s more, Becton Dickinson is not a top-10 holding (it’s No. 16, ...

Becton Dickinson and Co, iShares U.S. Pharmaceuticals ETF, BlackRock Health Sciences Trust. Read 's Market Analysis on Investing.com ...

The "United States Multiple Myeloma Market Report by Drugs Types, Disease Types, End User, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.The United States ...